Phase II trial of pegylated liposomal doxorubicin as consolidation chemotherapy in patients with stage III or IV ovarian or primary peritoneil carcinoma.

被引：0
|
作者：
Disilvestro, PA
Fisher, M
Pearl, M
Valea, F
Buhl, A
Chalas, E
机构：
[1] Women & Infants Hosp Rhode Isl, Providence, RI USA
[2] SUNY Stony Brook, Stony Brook, NY 11794 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5112
引用
收藏
页码：477S / 477S
页数：1
相关论文
共 50 条
  • [41] A phase II study of liposomal doxorubicin in recurrent epithelial ovarian carcinoma
    Arcuri, C
    Sorio, R
    Tognon, G
    Gambino, A
    Scalone, S
    Lucenti, A
    Caffo, O
    Valduga, F
    Arisi, E
    Galligioni, E
    TUMORI, 2004, 90 (06) : 556 - 561
  • [42] Neoadjuvant chemotherapy in patients with stage III esophageal carcinoma.
    Witthoeft, T
    Homann, N
    Ludwig, D
    Wiedemann, G
    Herrlinger, KR
    STange, EF
    GASTROENTEROLOGY, 2000, 118 (04) : A39 - A39
  • [43] Phase II Clinical Trial of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having a Therapeutic History of Platinum-based Chemotherapy: A Phase II Study of the Japanese Gynecologic Oncology Group
    Katsumata, Noriyuki
    Fujiwara, Yasuhiro
    Kamura, Toshiharu
    Nakanishi, Toru
    Hatae, Masayuki
    Aoki, Daisuke
    Tanaka, Kenichi
    Tsuda, Hiroshi
    Kamiura, Shoji
    Takehara, Kazuhiro
    Sugiyama, Toru
    Kigawa, Junzo
    Fujiwara, Keiichi
    Ochiai, Kazunori
    Ishida, Ryo
    Inagaki, Mitsuo
    Noda, Kiichiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (11) : 777 - 785
  • [44] A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma
    Valerio, MR
    Tagliaferri, P
    Raspagliesi, F
    Fulfaro, F
    Badalamenti, G
    Arcara, C
    Cicero, G
    Russo, A
    Venuta, S
    Guarneri, G
    Gebbia, N
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 : 79 - 85
  • [45] Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin -: Analysis of toxicities and predictors of outcome
    Safra, T
    Groshen, S
    Jeffers, S
    Tsao-Wei, DD
    Zhou, LY
    Muderspach, L
    Roman, L
    Morrow, CP
    Burnett, A
    Muggia, FM
    CANCER, 2001, 91 (01) : 90 - 100
  • [46] A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer
    del Carmen, Marcela G.
    Micha, John
    Small, Laurie
    Street, Daron G.
    Londhe, Anil
    McGowan, Tracy
    GYNECOLOGIC ONCOLOGY, 2012, 126 (03) : 369 - 374
  • [47] Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment
    Vorobiof, DA
    Rapoport, BL
    Mahomed, R
    Karime, M
    MELANOMA RESEARCH, 2003, 13 (02) : 201 - 203
  • [48] Phase II trial of pegylated-liposomal doxorubicin (Doxil™) in renal cell cancer
    Skubitz, KM
    INVESTIGATIONAL NEW DRUGS, 2002, 20 (01) : 101 - 104
  • [49] Phase II Trial of Pegylated-Liposomal Doxorubicin (Doxil™) in Renal Cell Cancer
    Keith M. Skubitz
    Investigational New Drugs, 2002, 20 : 101 - 104
  • [50] Phase II study of pegylated liposomal doxorubicin (Caelyx) in advanced hepatocellular carcinoma (HHC).
    Ruff, P
    Moodley, SD
    Rapoport, BL
    Chasen, MR
    Jacobs, C
    Hacking, D
    Voroblof, DA
    ANNALS OF ONCOLOGY, 2000, 11 : 69 - 70
12345